An update on recent cutting-edge trials: Treatments now available for newly diagnosed patients with mHSPC
Prostate cancer accounts for around one fifth of all male cancers, and most men with prostate cancer receive hormone therapy. This is often effective, however, in most cases progression occurs over time. This training course explores the latest clinical trials investigating new treatment options for patients with newly diagnosed mHSPC, including discussion of the ramifications of their findings for treatment in both the USA and Europe.
Immunotherapies are a relatively recent addition to the treatment armamentarium in GU oncology. This training course shares the latest information and expert opinion on the place of immunotherapy in the treatment of GU tumours, including guidance on the identification and management of immunotherapy-associated side effects.